🇺🇸 FDA
Patent

US 8933031

Polypeptide inhibiting angiogenesis and application thereof

granted A61KA61K38/00A61P

Quick answer

US patent 8933031 (Polypeptide inhibiting angiogenesis and application thereof) held by SHANGHAI FIRST PEOPLE'S HOSPITAL expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SHANGHAI FIRST PEOPLE'S HOSPITAL
Grant date
Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/00, A61P, A61P27/02, A61P9/00